Trump administration's National Science Foundation research funding cuts blocked by judge
A federal judge has blocked President Trump's administration from making drastic cuts to research funding provided by the National Science Foundation.
U.S. District Judge Indira Talwani in Boston struck down on Friday a policy change that could have stripped universities of tens of millions of dollars in research funding. The universities argued the move threatened critical work in artificial intelligence, cybersecurity, semiconductors and other technology fields.
Talwani said the change, announced by the NSF in May, was arbitrary and capricious and contrary to law.
An email by the Associated Press on Saturday to the NSF was not immediately returned.
At issue are "indirect" costs, expenses such as building maintenance and computer systems that aren't linked directly to a specific project. Currently, the NSF determines each grant recipient's indirect costs individually and is supposed to cover actual expenses.
The Trump administration has dismissed indirect expenses as "overhead" and capped them for future awards by the NSF to universities at 15 % of the funding for direct research costs.
The University of California, one of the plaintiffs, estimated the change would cost it just under $100 million a year.
Judges have blocked similar caps that the Trump administration placed on grants by the Energy Department and the National Institutes of Health.
In a recent interview on "CBS Mornings Plus," Todd Wolfson, president of the American Association of University Professors — whose organization sued the Trump administration over federal funding cuts to Columbia University — said examples of research that has been cut includes a research project that looks at discerning when AI is making fake videos or a project that examines when people start to believe lies that are repeatedly told.
"We are losing all the critical research that helps us understand truth and fiction in our social media platforms, whether it's Facebook or X or any other platform," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Podcast Bro Theo Von Questions How 'America First' Trump Really Is Amid Potential Iran War
Popular podcast host Theo Von joined Democratic Rep. Ro Khanna (Calif.) Friday in taking a hard stance against potential U.S. involvement in the Israel-Iran conflict. Khanna appeared on Von's podcast 'This Past Weekend' to discuss several topics, from foreign affairs to AI. At one point in the segment, Khanna promoted the War Powers Resolution, a bipartisan bill he introduced with Republican Rep. Thomas Massie (Ky.) aimed at prohibiting U.S. armed forces from unauthorized hostilities in Iran. During his discussion with Von, Khanna noted several people in MAGA's base who have been vocal about the U.S. not going to war with Iran, including Tucker Carlson and Rep. Marjorie Taylor Greene (Ga.). Von agreed with the two conservatives, stating, 'this is a horrible idea.' 'Yeah, people say, 'Well, you don't know a ton about the Middle East.' Like, that's fine. I don't want people I know, my friends, getting called up. I don't want the children of my friends getting called over to die,' Von said. 'I don't even understand how it's an option.' Von, who had Donald Trump on his podcast last year, helped the president reach younger male voters during the 2024 presidential election. Khanna remarked on the influence of Von's interview with Trump, stating the podcaster made the president 'the most human that I've actually seen him,' after the two opened up about the president's brother, alcoholism and cocaine. Last month, Von performed a controversial comedy act at a military base in Qatar before Trump addressed U.S. and Qatari troops. The podcast host has seemingly gotten closer to the Trump family, even having dinner with Ivanka and her husband, Jared Kushner, after they attended his comedy show in Miami. Miami looked good on you @TheoVon ! Come back and visit us soon !😎 — Ivanka Trump (@IvankaTrump) May 14, 2025 Now, however, Von is beginning to question the 'America First' claims that Trump made during his campaign. When Khanna asked Von if he knew anyone who was supporting the idea of the U.S. going to war with Iran, Von responded, 'Nobody.' I asked @TheoVon if he knows anyone who says we should go to war with Nobody. I feel like it was supposed to be America first. — Ro Khanna (@RoKhanna) June 20, 2025 Von went on to tell Khanna that 'it feels like we are just working for Israel,' and that he believes a lot of Americans are beginning to feel 'disillusioned' by U.S. leaders. 'I felt like it was supposed to be America first, like, we're focusing on, like, 'What are we doing to get things back into America,' right? To like, increase like the purpose of being an American, to refill our hearts with blood and ... make us feel something again here, and make us be excited about being an American,' Von said. JD Vance Tells Theo Von Musk Made A 'Huge Mistake' Going After Trump Exclusive: Israel Seeks Swift Action On Iran, Sources Say, With A Split U.S. Administration Trump Says He Should've Gotten 5 Nobel Peace Prizes While Continuing To Weigh Iran Strikes
Yahoo
23 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Christina Bohannan makes third run for Iowa's 1st Congressional District
Jun. 21—History shows that just because a candidate makes multiple attempts to win an election doesn't mean they can't eventually pull through. U.S. Rep. Mariannette Miller-Meeks lost a number of times to Dave Loebsack before winning Iowa's 1st Congressional District seat in a close 2020 election. Now her past Democratic challenger, Christina Bohannan, is attempting the same thing for the 2026 election cycle, provided she is the favorite in the primary. On June 17, Bohannan announced her campaign to take on Miller-Meeks once again. In a press release, her campaign said Bohannan nearly defeated Miller-Meeks in 2024 — less than 800 votes decided the election — and that the Democrat "outworked, outraised and outmatched her." Bohannan said, "Mariannette Miller-Meeks has had three terms in Congress — three chances to do right by the people of Iowa. Instead, she has taken over $4 million from corporate special interests and done nothing but vote their way. And she has put partisan politics over Iowans again and again. From cutting billions of dollars from Medicaid in the Trump Administration's One Big Beautiful Bill, to siding with DOGE's cuts to Social Security and enabling unelected, unaccountable billionaires like Elon Musk, Bohannan said the Republican congresswoman has forgotten about her constituents. "It's time someone put Iowa first," Bohannan said. Bohannan went on to say Miller-Meeks needs to explain "why she keeps putting Washington special interests first." The Democratic challenger claimed Miller-Meeks supported Trump's One Big Beautiful Bill, repeatedly voted for cost-increasing tariffs and is a member of the DOGE Caucus. Bohannan previously worked as an engineer and taught at the University of Iowa College of Law for 20 years. She also worked as an elected legislator for the Iowa House, defeating a 20-year incumbent in District 85. Bohannan is running for Congress because she believes in a government that works for the people. In May, another Democrat announced he would be running for Iowa's 1st Congressional District. Bob Krause, a former legislator who also tried running for U.S. Senate, announced his campaign with the slogan "Flip The House With Krause." Krause said Miller-Meeks votes "like Trump's rubber stamp." Travis Terrell, a Democrat from Johnson County, also announced his bid for Iowa's 1st Congressional District race. His campaign page on Facebook notes he is a working-class, New Deal Democrat fighting for healthcare, fair wages and a government that serves other working-class people and not billionaires. In addition to Miller-Meeks likely running for the seat, fellow Republican and former primary challenger David Pautsch announced in February that he would also be running for the seat. Pautsch touts himself as a MAGA Republican. He has been critical of Miller-Meeks, saying she is not conservative enough.
